Chinese Cancer Biotech Avistone Raises $200 Million in Funding Round

(Bloomberg) — Chinese biotechnology company Avistone Pharmaceuticals raised more than $200 million in a series A funding round led by Vivo Capital in one of the largest such deals for the sector.

The investment will support the combination of Avistone with Pearl Biotechnology Co. to create an integrated oncology platform. It will also fund the development of Avistone’s existing drug candidates and the expansion of its pipeline.